Naomi B. Haas - Concepedia

Author

Naomi B. Haas

Also Known As

Joseph A. Fraietta, Laird, A. Douglas, N B Haas, N Haas, N. B. Haas, N. Haas, N.B. Haas, Naomi B Haas, Naomi B. Haas, Naomi Balzer Haas

530

Publications

13.6K

Citations

H-Index

115

Concepts

All Affiliations

University of Pennsylvania Fox Chase Cancer Center Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Massachusetts General Hospital

About

Naomi B. Haas is an author at University of Pennsylvania specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	58	4.8K
2	Health Sciences	10	10	417
3	Natural Sciences	3	3	191
4	Public Health	2	2	52
5	Allergy	2	2	35

Naomi B. Haas

120

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, New England Journal of Medicine	2021	708
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. A.S. Lübbe, Christian Bergemann, Hanno Riess, PubMed Magnetic FluidsPharmacotherapyAdvanced Solid TumorsClinical ExperiencesOncology	1996	653
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Journal of the National Comprehensive Cancer Network	2022	627
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial Naomi B. Haas, Judith Manola, Robert G. Uzzo, The Lancet UrologyGenitourinary CancerMedicinePharmacologyClinical Trials	2016	625
Akt-Dependent Metabolic Reprogramming Regulates Tumor Cell Histone Acetylation Joyce V. Lee, Alessandro Carrer, Supriya Shah, Cell Metabolism ChromatinChromatin RemodelingMetabolic ReprogrammingMedicineMetabolic Remodeling	2014	566
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Journal of Clinical Oncology	2012	455
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial David C. Smith, Matthew R. Smith, Christopher J. Sweeney, Journal of Clinical Oncology	2012	442
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma Robert J. Motzer, Naomi B. Haas, Frede Donskov, Journal of Clinical Oncology	2017	382
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study Aaron R. Hansen, Christophe Massard, Patrick A. Ott, Annals of Oncology	2018	364
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer Eric K. Rowinsky, Garry Schwartz, Jared Gollob, Journal of Clinical Oncology	2004	323

Page 1